Expertise in
10
conditions

Dr. Gregory K. Friedman

Hematology | Oncology
UT MD Anderson Cancer Center
210 Ashville Ave # 408, 
Cary, NC 
Clinical Trials:Currently Recruiting for 3 Trials
Accepting New Patients
Expertise in
10
conditions
UT MD Anderson Cancer Center
210 Ashville Ave # 408, 
Cary, NC 

Overview

Gregory Friedman is a Hematologist and an Oncologist practicing medicine in Cary, North Carolina.

Dr. Friedman is highly rated in 10 conditions, according to our data. His clinical expertise encompasses Gliomatosis Cerebri, Glioma, Brain Tumor, Posterior Fossa Tumor, and Tissue Biopsy.

He is actively involved in clinical research, co-authoring 98 peer reviewed articles and participating in 23 clinical trials. Dr. Friedman is currently accepting new patients.

Specialties

Hematology
Oncology

Licenses

Pediatric Hematology-Oncology in AL

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Community Health
  • EPO
  • HMO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Oscar
  • EPO
  • HMO
  • PPO

Locations

UT MD Anderson Cancer Center
210 Ashville Ave # 408, Cary, NC 27518

Additional Areas of Focus

Dr. Friedman has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)
Neurofibromatosis Type 1 (NF1)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

23 Clinical Trials

A Phase 1/2 Study of DS-8201a (NSC# 807708) in Children, Adolescents, or Young Adults With Recurrent Osteosarcoma, Wilms Tumor, and Desmoplastic Small Round Cell Tumor
A Phase 1/2 Study of DS-8201a (NSC# 807708) in Children, Adolescents, or Young Adults With Recurrent Osteosarcoma, Wilms Tumor, and Desmoplastic Small Round Cell Tumor
Enrollment Status: Recruiting
Publish Date: September 08, 2026
Intervention Type: Procedure, Biological
Study Drug: Trastuzumab Deruxtecan
Study Phase: Phase 2
Phase 1 Trial of Engineered HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors
Phase 1 Trial of Engineered HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors
Enrollment Status: Recruiting
Publish Date: September 04, 2026
Intervention Type: Biological
Study Drug: G207
Study Phase: Phase 1
A Phase 1/2 Study of Tegavivint (NSC#826393) in Children, Adolescents, and Young Adults With Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
A Phase 1/2 Study of Tegavivint (NSC#826393) in Children, Adolescents, and Young Adults With Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
Enrollment Status: Recruiting
Publish Date: August 25, 2026
Intervention Type: Procedure, Drug
Study Drug: Tegavivint
Study Phase: Phase 1/Phase 2
Phase 2 Trial of XL184 (Cabozantinib) an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults With Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors
Phase 2 Trial of XL184 (Cabozantinib) an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults With Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Drug, Other
Study Drugs: Cabozantinib, Cabozantinib-S-Malate
Study Phase: Phase 2
A Phase 1/2 Trial of CBL0137 (NSC# 825802) in Patients With Relapsed or Refractory Solid Tumors Including CNS Tumors and Lymphoma
A Phase 1/2 Trial of CBL0137 (NSC# 825802) in Patients With Relapsed or Refractory Solid Tumors Including CNS Tumors and Lymphoma
Enrollment Status: Suspended
Publish Date: August 25, 2026
Intervention Type: Drug, Procedure
Study Drug: FACT Complex-Targeting Curaxin CBL0137
Study Phase: Phase 1/Phase 2
A Phase 1 Trial of the CD123 X CD3 DART Molecule Flotetuzumab (NSC#808294) in Children, Adolescents, and Young Adults With Relapsed or Refractory Acute Myeloid Leukemia
A Phase 1 Trial of the CD123 X CD3 DART Molecule Flotetuzumab (NSC#808294) in Children, Adolescents, and Young Adults With Relapsed or Refractory Acute Myeloid Leukemia
Enrollment Status: Active_not_recruiting
Publish Date: August 24, 2026
Intervention Type: Drug, Biological
Study Drugs: Cytarabine, Flotetuzumab
Study Phase: Phase 1
A Randomized, Open-Label Phase 1/2 Study Evaluating Ramucirumab in Pediatric Patients and Young Adults With Relapsed, Recurrent, or Refractory Desmoplastic Small Round Cell Tumor
A Randomized, Open-Label Phase 1/2 Study Evaluating Ramucirumab in Pediatric Patients and Young Adults With Relapsed, Recurrent, or Refractory Desmoplastic Small Round Cell Tumor
Enrollment Status: Completed
Publish Date: August 07, 2026
Intervention Type: Drug
Study Drugs: Ramucirumab, Cyclophosphamide, Vinorelbine
Study Phase: Phase 1/Phase 2
A Phase 2 Study of Dabrafenib (NSC# 763760) With Trametinib (NSC# 763093) After Local Irradiation in Newly-Diagnosed BRAF V600-Mutant High-Grade Glioma (HGG)
A Phase 2 Study of Dabrafenib (NSC# 763760) With Trametinib (NSC# 763093) After Local Irradiation in Newly-Diagnosed BRAF V600-Mutant High-Grade Glioma (HGG)
Enrollment Status: Active_not_recruiting
Publish Date: July 10, 2026
Intervention Type: Procedure, Radiation, Drug
Study Drugs: Dabrafenib Mesylate, Trametinib Dimethyl Sulfoxide
Study Phase: Phase 2
Phase II Clinical Trial of HSV G207 With a Single 5 Gy Radiation Dose in Children With Recurrent High-Grade Glioma
Phase II Clinical Trial of HSV G207 With a Single 5 Gy Radiation Dose in Children With Recurrent High-Grade Glioma
Enrollment Status: Withdrawn
Publish Date: February 10, 2026
Intervention Type: Biological
Study Drug: Biological G207
Study Phase: Phase 2
A Phase 1/ 2 Study of BAY 1895344 (Elimusertib, NSC#810486) in Pediatric Patients With Relapsed or Refractory Solid Tumors
A Phase 1/ 2 Study of BAY 1895344 (Elimusertib, NSC#810486) in Pediatric Patients With Relapsed or Refractory Solid Tumors
Enrollment Status: Active_not_recruiting
Publish Date: January 23, 2026
Intervention Type: Drug
Study Drug: Elimusertib
Study Phase: Phase 1/Phase 2
View 7 Less Clinical Trials

98 Total Publications

Oncolytic viruses enhance CAR-T activity for the treatment of pediatric diffuse midline gliomas.
Oncolytic viruses enhance CAR-T activity for the treatment of pediatric diffuse midline gliomas.
Journal: Molecular therapy. Oncology
Published: June 26, 2026
Similar Doctors
Expertise in
20
conditions
Dr. Nigel S. Key
Hematology | Oncology
Expertise in
20
conditions
Dr. Nigel S. Key
Hematology | Oncology
Referral may be required

UNC Hospitals Outpatient Center At Eastowne

100 Eastowne Dr, 
Chapel Hill, NC 
 (19.9 miles away)
984-974-2695
Languages Spoken:
English, French
See accepted insurances
Accepting New Patients
Offers Telehealth

Nigel Key is a Hematologist and an Oncologist practicing medicine in Chapel Hill, North Carolina. Dr. Key is highly rated in 20 conditions, according to our data. His clinical expertise encompasses Hemophilia B, Hemophilia A, Blood Clots, and Sickle Cell Disease. Dr. Key is currently accepting new patients.

Expertise in
20
conditions
Dr. Jatin P. Shah
Hematology | Oncology
Expertise in
20
conditions
Dr. Jatin P. Shah
Hematology | Oncology
Referral may be required

UT MD Anderson Cancer Center

210 Ashville Ave # 408, 
Cary, NC 
 (0.1 miles away)
713-792-6161
Languages Spoken:
English

Jatin Shah is a Hematologist and an Oncologist practicing medicine in Cary, North Carolina. Dr. Shah is highly rated in 20 conditions, according to our data. His clinical expertise encompasses Thyroid Cancer, Salivary Gland Tumors, Tongue Cancer, Thyroidectomy, and Glossectomy.

Expertise in
16
conditions
Dr. David M. Ashley
Hematology | Oncology
Expertise in
16
conditions
Dr. David M. Ashley
Hematology | Oncology
Referral may be required

Duke University Hospital

2301 Erwin Rd, 
Durham, NC 
 (21.2 miles away)
919-668-6288
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

David Ashley is a Hematologist and an Oncologist practicing medicine in Durham, North Carolina. Dr. Ashley is highly rated in 16 conditions, according to our data. His clinical expertise encompasses Astrocytoma, Glioblastoma, Glioma, and Gliomatosis Cerebri. Dr. Ashley is currently accepting new patients.

Frequently Asked Questions about Dr. Gregory K. Friedman

How do I make an appointment with Dr. Gregory K. Friedman?

You can book an appointment with Dr. Gregory K. Friedman by calling their office at 713-792-6161. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Gregory K. Friedman a top-rated expert for Gliomatosis Cerebri?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Gregory K. Friedman is classified as an Distinguished expert for Gliomatosis Cerebri, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Gregory K. Friedman specialize in?

While Dr. Gregory K. Friedman is a Hematology, they have specific expertise in Gliomatosis Cerebri, Glioma, and Brain Tumor. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Gregory K. Friedman participate in research or clinical trials?

Yes. Dr. Gregory K. Friedman has published 98 articles and abstracts on conditions like Gliomatosis Cerebri. You can view a list of Dr. Gregory K. Friedman's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Gregory K. Friedman accept my insurance?

Dr. Gregory K. Friedman accepts most major insurance plans, including Community Health and Health Care Services Corporation. We recommend calling the office directly at 713-792-6161 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Friedman's expertise for a condition
ConditionClose
    View All 17 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile